Vaccines - Zambia

Zambia

In Zambia, the revenue in the Vaccines market is estimated to reach US$55.94m in 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of -10.95%, ultimately leading to a market volume of US$31.32m by 2029.
When compared globally, United States is projected to generate the highest revenue in the Vaccines market, amounting to US$29,120.00m in 2024.
Zambia is witnessing a growing demand for vaccines, driven by an increased awareness about the importance of immunization.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Zambia has been on the rise in recent years due to various factors.

Customer preferences: Zambians have become more health-conscious and aware of the importance of preventing diseases through vaccination. This has led to an increase in demand for vaccines, especially among children and vulnerable populations. Additionally, the government has been implementing various vaccination programs, which has further boosted the demand for vaccines.

Trends in the market: The vaccines market in Zambia has been growing steadily, with an increasing number of pharmaceutical companies entering the market. This has led to increased competition and a wider range of vaccines being available to the public. Additionally, the market has seen a shift towards more advanced and effective vaccines, which has further boosted demand.

Local special circumstances: Zambia has a high burden of infectious diseases, including malaria, tuberculosis, and HIV/AIDS. This has created a need for vaccines to prevent these diseases, especially among vulnerable populations such as children and pregnant women. Additionally, the country has a large rural population, which can make it difficult to distribute vaccines to remote areas.

Underlying macroeconomic factors: The Zambian economy has been growing steadily, which has led to an increase in disposable income and a higher demand for healthcare services. Additionally, the government has been investing in the healthcare sector, which has led to improved access to healthcare services and an increase in demand for vaccines. However, the country still faces challenges such as a high poverty rate and limited healthcare infrastructure, which can affect the accessibility of vaccines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.